Reporter brief
HMGA1-HP1β peptide therapy extended lifespan in a mouse model of Hutchinson-Gilbert progeria syndrome
What happened
Researchers studied the HMGA1-HP1β regulatory axis in a mouse model of Hutchinson-Gilford progeria syndrome (LmnaG609G/G609G mice). They developed a peptide called UHP based on the HMGA1-HP1β binding region and found it reduced cellular senescence markers and significantly extended lifespan in the progeria mice, reportedly by stabilizing HP1β and suppressing senescence-associated secretory factors.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Animal; Animal.
LmnaG609G/G609G mice (genetic mouse model of Hutchinson-Gilford progeria syndrome), naturally aging mice, Hmga1-/- mice
- Design
- Animal
- Sample
- —
- Journal
- Nature Communications
- Published
- Aug 19, 2026
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Gene therapy for ageing timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.